

CURRICULUM VITAE
July 2005

PERSONAL

NAME: Ralph H. Raasch

ADDRESS: Residence: 211 Morningside Drive
Carrboro, North Carolina 27510

Office: School of Pharmacy
Beard Hall CB# 7360
University of North Carolina
Chapel Hill, NC 27599-7360

TELEPHONE: Residence (919) 929-5972
Office (919) 962-0071
FAX (919) 962-0644
E-mail ralph_raasch@unc.edu

DATE OF BIRTH: August 11, 1949

PLACE OF BIRTH: Milwaukee, Wisconsin

DEPENDENTS: Nancy, Wife
Holly, Daughter

EDUCATION

Undergraduate Education

University of California, Davis.
Bachelor of Science, Mathematics, with Highest Honors, 1971.

Professional Education

University of California, San Francisco.
School of Pharmacy, Doctor of Pharmacy, 1975.

Residency

Resident in Hospital and Clinical Pharmacy.
University of California Hospitals and Clinics, and School of
Pharmacy, San Francisco, 1975-1976.

PROFESSIONAL EXPERIENCE

Vice Chair for Professional Education, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, The University of North Carolina at Chapel Hill, July 2005-present.

Interim Chair, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, The University of North Carolina at Chapel Hill, November 2002-September 2004.

University Professor of Distinguished Teaching, The University of North Carolina at Chapel Hill, April 2001

Associate Professor of Pharmacy and Clinical Associate Professor of Medicine, Schools of Pharmacy and Medicine, The University of North Carolina at Chapel Hill, September, 1985-Present.

Director, Office of Curricular Affairs, School of Pharmacy, August 1998-November 2002.

Assistant Professor of Pharmacy, Division of Pharmacy Practice, School of Pharmacy, University of North Carolina, Chapel Hill, September 1978-August, 1985.

Clinical Assistant Professor of Medicine, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, March 1979-August, 1985.

Director of the Drug Information Center, North Carolina Memorial Hospital and School of Pharmacy, University of North Carolina, Chapel Hill, January-July, 1977.

Instructor, Division of Pharmacy Practice, School of Pharmacy, University of North Carolina, Chapel Hill, September, 1976-September, 1978.

Staff Pharmacist, Stanford University Medical Center, Stanford, California, July-August, 1976.

UNIVERSITY SERVICE

Faculty Council, School of Pharmacy Representative, 1990-1993, 1999-2002.

University and Hospital Committees

Committee for Awards for Excellence in Undergraduate Teaching 1981, 1982.

University Teaching Awards Committee, 2001-4.

Chair, General Clinical Research Center Scientific Advisory Committee, October 2002-present. Committee Member, October 1992-present.

Antibiotic Subcommittee of the Pharmacy and Therapeutics Committee, 1994-present.

School of Pharmacy, University of North Carolina, Faculty Committees

Accreditation --2004-present

Admissions --1998-present

Scholastic Achievement and Progression – 1998-present

Director, Doctor of Pharmacy Program – 1981-1997

Master's Thesis Committees

William T. Sawyer: Computer-assisted warfarin therapy: a comparison of two models, May 1977.

Vicky Lee Rhodes: Propranolol and hydralazine in the treatment of essential hypertension: a preliminary report, July 1978.

Kathy M. Teasley: Immunocompetency in patients on chronic hemodialysis: effect of nutritional status, November 1978.

James T. Burke: The pharmacokinetics of intravenous chloramphenicol sodium succinate in patients with normal and impaired hepatic function, May 1979.

Michael D. Thorn: A comparative review of the statistical quality and research quality of the medical and pharmacy literature, December 1981.

Mary C. Plonski: Mixed amino acids in acute renal failure: a retrospective study, May 1982.

Carl J. Tullio: Comparison of TPN complications in patients with and without consultation by a nutrition support service, May 1982.

Vivianne Benaim: Host tumor response to glucose and fat based TPN in rats, October 1982.

Steven Kotter: Acceleration of peritoneal dialysis clearance with docusate sodium (DSS), April 1983.

Amy Northup: The development of a nutrition support committee: a community hospital model, April 1984 (Chair).

Lee Ann Yount: The impact of a pharmacy-based aminoglycoside monitoring service on patient and pharmacy costs, July 1986 (Chair).

Gregory Dozier: The association of heparin-induced elevation of plasma transaminase concentrations with histological liver changes in a rat model, December 1987.

Gill Abernathy: The efficacy of delivery of enteral nutrition in hospitalized patients, April 1988.

Richard Drew: Randomized, prospective, double-blind evaluation of the efficacy of 0.9% sodium chloride with and without heparin sodium to maintain patency of peripheral intravenous and arterial infusion devices, May 1989 (Chair).

William Pickard: A retrospective review of 1987 amphotericin B use at Duke University Hospital, August 1993 (Chair).

Kristan T. Norris: Effect of gentamicin concentrations on the incidence of thrombophlebitis, August 1994 (Chair).

John D. Murray: Effect of lung disease on energy expenditure determination by indirect calorimetry, May 1996 (Chair).

Nopanan Yaibinathes: The evaluation of empirical antimicrobial treatments and patient outcomes in sepsis, October 1996.

Jungeun Ahn: Comparison of measured and estimated creatinine clearances in patients with non-insulin-dependent diabetes mellitus, May 1997 (Chair).

Xingyue Huang: Economic assessment of three antimicrobial therapies for uncomplicated urinary tract infection in women, May 1998.

Yu-Chen Yeh: Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B, May 2000.

Fellows Precepted (with Post-Fellowship Employment)

David E. Martin, PharmD, 1992-3 (Clinical Pharmacology, SKB)
Katy H.P. Moore, PharmD, 1993-4 (Pharmacology, GlaxoWellcome)
Deborah Copeland, PharmD, 1994-5 (School of Pharmacy, MCP)
John Wakeford, PharmD, 1995-6 (Hepatology, GlaxoWellcome)
Jody Wiedler, PharmD, 1996-7 (Medical Affairs, Roche)
John C. Rublein, PharmD, 1998-9 (Infectious Diseases, UNC)
Naumann Chaudry, PharmD, 1999-2000 (Medical Affairs, Pfizer)

Specialty Pharmacy Residents in Infectious Diseases (Post-Residency Position)

Eric Wolford, PharmD, 1995-6 (ID Fellowship, UNC)
Mike Dietrich, PharmD, 1996-7 (ID Fellowship, UNC)
Melissa Faris, PharmD, 1997-8 (Medical Affairs, GlaxoWellcome)
John Williamson, PharmD, 1998-9 (ID Clinical Specialist, Wake Forest)
Holly Hogan, PharmD, 1999-2000 (Clinical Specialist, Michigan)
Amanda Corbett, PharmD, 2000-1 (ID Fellowship, UNC)
Brian Donovan, PharmD, 2001-2 (Clinical Specialist, Hahnemann Hospital)
Olga Klivanov, PharmD, 2002-3 (Clinical Assistant Professor, Temple Univ.)
Todd Correll, PharmD, 2003-4 (Clinical Specialist in ID, UNC Hospitals)
Will Musick, PharmD, 2004-5 (ID Clinical Specialist, Houston-Methodist)
Sonak Pastakia, PharmD, 2005-6

Teaching Activities

School of Pharmacy

Course Director, Pharmacy 75 and 152: Pathophysiology and Therapeutics.
- Infectious Diseases and Gastroenterology Modules: Pharm.D. Program.
Facilitator, Pharmacy 169: Problems in Pharmacotherapy.
Course Director, Pharmacy 115: Infectious Diseases Elective.

Pharm.D. Clerkship Preceptor, Infectious Diseases Consult Service.

Director and Preceptor, Infectious Diseases Specialty Pharmacy Resident Program.

UNC Hospitals

Clinical Pharmacist, Infectious Diseases Consult Service, Departments of Pharmacy and Medicine, University of North Carolina and UNC Hospitals.

School of Medicine

Seminar preceptor, Principles of Pharmacology.

OTHER PROFESSIONAL ACTIVITIES

Member, Editorial Advisory Board, Panel on General Medicine (1983-2000), Panel on STDs and HIV/AIDS (2000-present), The Annals of Pharmacotherapy.

Member, Pharmacist Committee, and Education and Professional Development Committee, American Society for Parenteral and Enteral Nutrition, 1989-1991.

Member, Research and Data Committee, American Society for Parenteral and Enteral Nutrition, 1993-1996.

Member, Examination Committee, Foreign Pharmacy Graduate Examination Commission, 1986-present.

Chairman, Publications Committee, Society of Infectious Disease Pharmacists, 1995.

Member, Pharmacotherapy Specialty Council, Board of Pharmaceutical Specialties, 1996-1999; Vice-Chair, 1998. Re-appointment 1999-2002; Vice-Chair, 1999; Chair, 2000-2001.

President, Triangle College of Clinical Pharmacy, ACCP Chapter, 1997.

Journal Referee: Annals of Pharmacotherapy, American Journal of Health-System Pharmacy, Blood, Journal of Infectious Disease Pharmacotherapy, JAIDS, Journal of Pharmacy Practice (Guest Editor, Vol. 12, Nos. 5-6, 1999).

Member, Certificate Program Review Committee, North Carolina Center for Pharmaceutical Care, 1999-present.

Regent, American College of Clinical Pharmacy, 2001-2003.
Chair and Board Liaison, ACCP Nominations Committee, 2001-3.
Member, ACCP Executive Committee, 2002-3.

LICENSURE TO PRACTICE: Registered Pharmacist, State of California, 1975.
Registered Pharmacist, State of North Carolina, 1990.

PROFESSIONAL CERTIFICATION:
Board of Pharmaceutical Specialties
Pharmacotherapy, 1993; Recertification by Exam, 2004.
With Added Qualifications in Infectious Diseases, 2002.

PROFESSIONAL SOCIETIES
American Society of Health-System Pharmacists
North Carolina Association of Pharmacists
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
Triangle College of Clinical Pharmacy
American Society for Microbiology
Society of Infectious Diseases Pharmacists
Infectious Diseases Society of America

HONORARY SOCIETIES:
Phi Beta Kappa, University of California, Davis, 1971.
Phi Kappa Phi, University of California, Davis, 1971.
Rho Chi, University of California, San Francisco, 1973.
Sigma Xi, University of North Carolina, Chapel Hill, 1983.
Chapter Secretary, Sigma Xi, 1987-95.

AWARDS
Regents Scholar, University of California, San Francisco, 1971.
Tanner Distinguished Teacher Award, University of North Carolina, Chapel Hill, 1979
Professor of the Year, UNC PharmD Program, Class of 1983, 1989, 1997
Instructor of the Year Award, UNC School of Pharmacy, Class of 1980, 1995, 1999, 2004.
Fellow, American College of Clinical Pharmacy, November 2000.
University Professor of Distinguished Teaching, University of North Carolina at Chapel Hill, April 2001.

GRANT AWARDS:

The effect of intravenous fat emulsion on the clinical course of pancreatitis in the rat, with L.J. Hak, Pharm.D., W.D. Heizer, M.D., V. Benaim, B.S. Funded by Abbott Laboratories, #1-0-101-4501-73144, 1981, \$3000.00.

The Clinical Cancer Education Program with co-investigators from the Schools of Medicine, Dentistry, Pharmacy, and Public Health, University of North Carolina, Chapel Hill, North Carolina. Funded by National Cancer Institute #5. R25 CA 17973. 1981-1983, 1983-1985.

The effect of nutritional substrate modification on host and tumor growth in the rat, University Research Council Grant. #1-0-101-4501-VP369. \$1438. 1981-1983; and North Carolina United Way, \$3,000, 1983-1983; and Cutter Medical, Berkeley, California, \$5,000, 1982-1983; (with L.J. Hak).

Effects of hypothyroidism on gentamicin nephrotoxicity in the rat. University Research Council Grant, #1-0-101-4501-VF777, \$1,500, 1983-1985 (with L.J. Hak).

Can thyroid hormone promote recovery from gentamicin nephrotoxicity? Pharmacy Foundation of North Carolina Faculty Research Award, \$1,500, 1985 (with L.J. Hak).

Enhancing information by Pharm.D. students. American Association of Colleges of Pharmacy GAPS Program, \$20,285; 1986-1987, Co-Investigator.

Health of the Public Program, Pew-Rockefeller Foundation, \$1.2 million, 1988-1989, Co-Investigator.

Clinical studies of antiretroviral therapies. NIH-National Institute of Allergy and Infectious Diseases, \$1.6 million, 1987-1992; renewal, \$3.9 million, 1992-1996; renewal 1996-2001; Co-Investigator.

Evaluation of the safety and pharmacokinetics of 3TC in combination with trimethoprim/sulfamethoxazole. Glaxo Research Institute, \$93,632, 1993-1994, Principal Investigator.

Efficacy and Safety of tailored vs. traditional tobramycin dosing for pulmonary exacerbations in patients with cystic fibrosis. Cystic Fibrosis Foundation, \$108,000; 1996-98, Co-Investigator.

Effect of Zosyn therapy on hematologic parameters and frequency of bleeding complications in surgical patients. Lederle Laboratories, \$1,500; 1996-97; Principal Investigator (for residency project).

Characterizing cytochrome P450 in HIV-1 infected women. Research Institute of the American College of Clinical Pharmacy, \$10,020, 1998; Co-investigator.

Clinical Research Curriculum Award. Co-Director. National Institutes of Health, 1999-2005. Renewed, 2005-2010. 2005-6 Total costs \$300,000.

North Carolina Collaborative Pediatric Clinical Research Unit. National Institutes of Health, 2004-2009, \$155,263; 2004. Co-Principal Investigator.

INTERNATIONAL AND NATIONAL PRESENTATIONS:

Treatment of thrombotic thrombocytopenic purpura (TTP) with anti-platelet drugs, 12th Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 8, 1977.

Use of a specific enzyme inhibitor, hematin, in the treatment of acute intermittent porphyria, 13th Annual ASHP Midyear Clinical Meeting, San Antonio, Texas, December 6, 1978.

Nutritional support of a patient with pancreatitis, 4th Clinical Congress of the American Society for Parenteral and Enteral Nutrition, Chicago, February 1, 1980.

Principles of therapy in gastrointestinal disease, 15th Annual ASHP Midyear Clinical Meeting, San Francisco, California, December 10, 1980.

The general approach to patient monitoring, The American Society for Parenteral and Enteral Nutrition Post-Graduate Course on Metabolic Monitoring of Nutrition Support, January 29, 1984, and January 21, 1985.

Metabolic monitoring of the critically ill patient receiving nutritional support, 19th Annual ASHP Midyear Clinical Meeting, Dallas, December 5, 1984.

Pharmacology and nutrition, 1st Venezuelan Symposium for Parenteral and Enteral Nutrition, Caracas, September 22-23, 1984; and Concepts of Parenteral and Enteral Nutrition, Central University of Venezuela, Caracas, September 24-28, 1984.

Current agents in the treatment of hypercholesterolemia, Update: Clinical Implications of Hypercholesterolemia, Indianapolis, December 1, 1987.

Clinical comparison of antihyperlipidemic agents, American Society of Hospital Pharmacists 45th Annual Meeting, San Francisco, June 6, 1988.

Lipid metabolism and utilization in patients on TPN, Update: Nutrition Support Services, Lynchburg, VA, May 12, 1989.

Evaluation of perioperative nutritional support, 14th Clinical Congress of the American Society for Parenteral and Enteral Nutrition, San Antonio, TX, January 30, 1990.

Management of the GI complications of AIDS, ACCP Regional Conference, Chicago, IL, May 3, 1990, and ACCP 1991 Winter Forum, Ft. Lauderdale, FL, February 13, 1991.

Clinical Practice: Dealing with the AIDS patient. ACCP 1990 Annual Meeting, San Francisco, CA August 8, 1990.

Nutrition support in cancer patients: point/counterpoint, 15th Clinical Congress of the American Society for Parenteral and Enteral Nutrition, San Francisco, CA January 29, 1991.

Pharmacologic considerations in critically ill patients receiving nutritional support, Management of acid-base disorders in the critically ill patient, and implications of nutritional support on pulmonary metabolism, 4th Venezuelan Congress for Parenteral and Enteral Nutrition, Caracas, November 25-26, 1991.

Management of infection in the febrile, neutropenic patient, British Columbia Cancer Agency Communities Oncology Program, Vancouver, May 8, 1992.

Application of basic science research in clinical nutrition, 1993 ACCP Annual Meeting, Reno, August 18, 1993.

ACCP Pharmacotherapy Exam Preparatory Course. Workshop: Fluid/Electrolytes and Nutrition, Orlando, February 10-11, 1995.

Therapeutic Debate: Helicobacter pylori treatment of patients with ulcer disease. ASHP 30th Annual Midyear Clinical Meeting, Las Vegas, 1995.

Acid/Base Balance: monitoring nutrition support in the ICU. ASPEN 20th Clinical Congress, Washington, 1996.

Therapeutic Debate: early intervention in HIV infection. ASHP 31st Annual Midyear Clinical Meeting, New Orleans, 1996.

Clinical Pearl: Allergic or not: what have you got? ASHP 31st Annual Midyear Clinical Meeting, New Orleans, 1996.

Therapeutic Debate: Medical Marijuana. ASHP 32nd Annual Midyear Clinical Meeting, Atlanta, 1997.

Pharmacotherapy of opportunistic infections. First Annual Conference of Infectious Diseases Pharmacotherapy, Orlando, 1998.

Mechanisms of bacterial resistance, and Problem pathogens: gram-positive organisms. ASHP Annual Meeting, Baltimore, 1998.

Microbiology Lab 101. Second Annual Conference of Infectious Diseases Pharmacotherapy, Orlando, 1999.

New Approaches to the Prevention and Treatment of Line-Related Infections, and Case Studies in the Management of Febrile Neutropenia. Third Annual Conference of Infectious Diseases Pharmacotherapy, Orlando, 2000.

Clinical Issues in Antimicrobial Resistance, ASHP Annual Meeting, Los Angeles, 2001.

PUBLICATIONS:

Textbook Chapters, Monographs, Bibliographies, Reviews

Pulliam CC and Raasch RH. Treatment of ischemic heart disease. In Gerbino PP (ed): Self-assessment on current knowledge in clinical pharmacy, Medical Examination Publishing Company, Garden City, NY, 1978, p 77-82.

Raasch RH, Heizer WD, Therapeutics bibliography for clinical pharmacists--gastroenterology. Am J Hosp Pharm. 1980; 37:412-4.

Raasch RH. Hyperlipidemias. In Koda-Kimble MA, Katcher BS, Young LY (eds): Applied Therapeutics for Clinical Pharmacists, 3rd Edition, Applied Therapeutics, Inc., San Francisco, 1983, pp. 651-62.

Raasch RH. How are diet and metabolism altered in cancer patients: In Anderson JJB (ed): Dietary Excesses and Health/Disease Implications. Health Sciences Consortium, Carrboro, NC, 1984, pp. 171-89.

Raasch RH. Endocrinology: A basic bibliography. Hosp Pharm 1986; 21:1186.

Hartzema AG, Raasch RH, Kessler JM, Thorn MD, Stigleman SE, Burseu J. The development of a personal clinical database. Am J Pharm Educ 1987;51:320-21.

Raasch RH. Diabetes mellitus learning system: Carbohydrate metabolism (unit 1), classification and pathophysiology (unit 2), and diagnosis and management (unit 3). Health Sciences Consortium, Chapel Hill, 1988.

Raasch RH. Aspirin, Dipyridamole, Dihydroergotomine/Heparin, Streptokinase, Ticlopidine, and Urokinase Drug Evaluation Monographs. In: Conner CS, Rumack BH (eds.), DRUGDEX Information System. Denver, CO: Micromedex, Inc. 1995.

Raasch RH. Hyperlipidemias. In Young LY, Koda-Kimble MA (eds): Applied Therapeutics - The Clinical Use of Drugs, 4th Edition, Applied Therapeutics, Inc., Vancouver, WA, 1988, pp. 1749-60.

Raasch RH. Endocrinology: a basic bibliography-1989. Hosp Pharm 1989;24:302.

Raasch RH. Hyperlipidemias. In Koda-Kimble MA, Young LY (eds.): Applied Therapeutics - The Clinical Use of Drugs, 5th Edition, Applied Therapeutics, Inc., Vancouver, WA, 1992, pp. 73-1 to 73-15.

Raasch RH. Endocrinology-1991. Hosp Pharm 1991;26:1092.

Raasch RH. Review of Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice, by Greene RJ and Harris ND. Ann Pharmacother 1993;27:1408.

Morgan AE, Raasch RH. Nutritional Concerns in Patients with AIDS. Health Sciences Consortium, Inc., Chapel Hill, NC 1993.

Raasch RH. Hyperlipidemia-A Basic Bibliography. Hosp Pharm 1994;29:952-3.

Raasch RH, Hopfer RL. Antifungal Agents. In: Munson PL, Mueller RA, Breese GR (eds): Principles of Pharmacology-Basic Concepts and Clinical Applications, Chapman and Hall, New York, 1995, pp. 1401-12.

Raasch RH. Osteomyelitis/Septic Arthritis. In: Koda-Kimble MA, Young LY (eds): Applied Therapeutics: The Clinical Use of Drugs, 6th Edition, Applied Therapeutics, Inc., Vancouver, WA, 1995, Ch. 65-1 to 65-12.

Raasch RH. Review of Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Hardman, JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Am. J. Pharm. Educ., 1996; 60:225.

Raasch RH. Review of Power Unseen: How Microbes Rule the World, by Dixon B. Am. J. Health-Syst. Pharm 1996; 53:2538.

Raasch RH. Review of Drug Therapy 1999: A Critical Review of Therapeutics, by Gibaldi M. Ann Pharmacother 2000;34:409.

Raasch, RH. Osteomyelitis/Septic Arthritis. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ (eds): Applied Therapeutics: The Clinical Use of Drugs, 7th Edition, Lippincott Williams & Wilkins, Philadelphia, 2001, Ch. 64-1 to 64-13.

Raasch RH. Pharmacology of Antimicrobials, Antifungals, and Antivirals. In: Tintinalli JE, Kelen GD, Stapczynski JS (eds): Emergency Medicine: A Comprehensive Study Guide, 6th Edition, McGraw-Hill, New York, 2004, Ch. 155.

Raasch, RH. Osteomyelitis/Septic Arthritis. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ (eds): Applied Therapeutics: The Clinical Use of Drugs, 8th Edition, Lippincott Williams & Wilkins, Philadelphia, 2004, Ch. 66.

Raasch RH. Review of Handbook of Food-Drug Interactions. McCabe BJ, Frankel EH, Wolfe JJ, 2003, CRC Press. J Nutr Educ Behavior 2004;36:113-4.

Raasch RH. Basic Issues for Research in Antibiotic Development, In: Evens RP, Covinsky JO (eds): Drug & Biological Development, From Molecule to Product and Beyond, Springer Verlag, 2005, In press.

Refereed Articles

Raasch RH. Analysis of drug information requests. Am J Hosp Pharm. 1977;34:809-10.

Raasch RH. Effects of dextran 70 on factor VIII activity. *Am J Hosp Pharm.* 1979; 36:89-91.

Webster PR, Heizer WD, Callahan WT, Hak LJ, Teasley KM, Raasch RH, Porter RS, Welch DW. Current therapy--guidelines for adult parenteral nutrition. *NC Med J.* 1979; 40:685-90.

Raasch RH. Clinical pharmacokinetics of heparin. *Drug Intell Clin Pharm.* 1980; 14:483-8.

Raasch RH, Hak LJ, Benaim V, Brower L, Levinson SL, Heizer WD. Effect of intravenous fat emulsion on experimental acute pancreatitis. *J Parenter Enter Nutr.* 1983; 7:254-6.

Sawyer WT, Raasch RH. Effect of heparin on prothrombin time. *Clin Pharm.* 1984; 3:192-4.

Hak LJ, Raasch RH, Hammer VB, Matthews T, Sandler RS, Heizer WD. Comparison of intravenous glucose and fat calories on host and tumor-growth. *JPEN* 1984;8:657-9.

Ulshen MH, Lyn-Cook L, Raasch RH. Effects of intraluminal epidermal growth factor on mucosal proliferation in the small intestine of adult rats. *Gastroenterology* 1986; 91:1134-40.

Berger RG, Featherstone GL, Raasch RH, McCartney WH, Hadler NM. Treatment of calcinosis universalis with low-dose warfarin. *Am J Med* 1987;83:72-6.

Perkins JB, Raasch RH. Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever. *Drug Intell Clin Pharm* 1987;21:343-5.

Raasch RH. Interactions of oral antibiotics and common chronic medications. *Geriatrics* 1987;42:69-74.

Hak LJ, Raasch RH. Use of aminoacids in patients with acute renal failure. *Nutr Clin Prac* 1988;3:19-22.

Abernathy GB, Heizer WD, Holcombe BJ, Raasch RH, Schegal KE, Hak LJ. Efficacy of tube feeding in supplying energy requirements of hospitalized patients. *JPEN* 1989;13:387-91.

Ujhelyi MR, Raasch RH, van der Horst CM, Mattern WD. Treatment of peritonitis due to *Curvularia* and *Trichosporon* with amphotericin B. *Rev Infect Dis* 1990;12:621-7.

Raasch RH. Pravastatin sodium, a new HMG-CoA reductase inhibitor. *DICP, Ann Pharmacother* 1991;25:388-94.

Aweeka FT, Gambertoglio JG, van der Horst C, Raasch RH, Jacobson MA. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS clinical trials group protocol 053). *Antimicrob Agents Chemother* 1992;36:1773-8.

Flores-Runk P, Raasch RH. Ticlopidine and anti-platelet therapy. *Ann Pharmacother* 1993;27:1090-8.

Martin DE, Raasch RH. Rifabutin: A new rifamycin for the prevention of atypical mycobacterial infection. *J Pharm Technol* 1994;10:197-203.

Moore KHP, Raasch RH, Brouwer KLR, Opheim K, Cheeseman SH, Eyster E, Lemon SM, van der Horst CM. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group Protocol 062). *Antimicrob Agents Chemother* 1995;39:2732-7.

Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. *J Clin Pharmacol* 1996;36:85-91.

Moore KHP, Yuen GT, Raasch RH, Eron JJ, Martin D, Mydlow PK, Hussey EK. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. *Clin Pharmacol Ther* 1996;59:550-8.

Ulshen MH, Raasch RH. Luminal epidermal growth factor preserves mucosal mass of small bowel in fasting rats. *Clin Sci* 1996;90:427-31.

Jacobson JM, Davidian M, Rainey PM, Hafner R., Raasch RH, Luft BJ. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. *Antimicrob Agents Chemother* 1996;40:1360-65.

Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure; Influence of hemodialysis and continuous ambulatory peritoneal dialysis. *Clin Pharmacol Ther* 1996; 60: 535-42.

Faris MA, Raasch RH, Hopfer RL, Butts JD. Treatment and prophylaxis of disseminated Mycobacteria avium complex in HIV-infected individuals. *Ann Pharmacother* 1998; 32:564-73.

Hafner R, Bethel J, Power M, Landry B, Banach M, Mole L, Standiford H, Follansbee S, Kumar P, Raasch R, Cohn D, Mushatt D, Drusano G. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. *Antimicrob Agents Chemother* 1998; 42:631-9.

Evers LB, Raasch RH. Treatment gap in lipid-lowering therapy. *J Pharm Prac* 1998; 11:318-22.

Raasch RH, Weber DJ. Infections in the intensive care unit. Appropriate antibiotic use. *Hosp Prac – A Special Report*, February 1999:53-64.

Weber DJ, Raasch RH, Rutala WA. Nosocomial infections in the ICU: The growing importance of antibiotic-resistant pathogens. *Chest* 1999;115:34S-41S.

Kashuba ADM, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. *Antimicrob Agents Chemother* 1999;43:1817-26.

Rublein JC, Eron JJ Jr, Butts JD, Raasch RH. Discontinuation rates for protease regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg. *Ann Pharmacother* 1999;33:899-905.

Huang X, Hartzema AG, Raasch RH, Kauf TL, Norwood GJ. Economic assessment of three antimicrobial therapies for uncomplicated urinary tract infection in women. *Clin Ther* 1999;21:1578-88.

Dietrich MA, Butts JD, Raasch RH. HIV-1 protease inhibitors: a review. *Infect Med* 1999;16:716-38.

Boger MS, Raasch RH. Inflammatory bowel disease: current pharmacotherapy issues. *J Pharm Prac* 1999;12:472-91.

Raasch RH. So you think you know how to grade a clerkship student? *South J Health-Syst Pharm* 1999;3:12-3.

Williamson JC, Virata SR, Raasch RH, Kylstra JA. Oxacillin-resistant *Staphylococcus aureus* endophthalmitis after ganciclovir implant. *Am J Ophthalmol* 2000;129:554-5.

Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM. Competing drug—drug interactions among multidrug regimens used in the treatment of HIV-infected subjects: ACTG 884. *AIDS* 2000;14:2495-2502.

Hafner R, Bethel J, Standiford HC, Follansbee S, Cohn DL, Polk RE, Mole L, Raasch R, Kumar P, Mushatt D, Drusano G. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. *Antimicrob Agents Chemother* 2001;45:1572-1577.

Williamson JC, Craft DW, Butts JD, Raasch RH. In vitro assessment of urinary isolates of ampicillin-resistant Enterococci. *Ann Pharmacother* 2002;36:246-50.

Weber DJ, Raasch RH, Rutala WA. Healthcare-acquired pneumonia. *Curr Treat Options Infect Dis* 2002;4:141-151.

Donovan BJ, Weber DJ, Rublein JC, Raasch RH. Treatment of tick-borne diseases. *Ann Pharmacother* 2002;36:1590-7.

Brock TP, Deloatch KH, McDermott JH, Joyner PU, Ellis-Nielsen AD, Raasch RH. Objective structured clinical examinations as an assessment tool in pharmacy curricula. *J Pharm Teach* 2002;9(2):1-16.

Leone PA, Raasch RH. Viral sexually transmitted diseases. *Curr Treat Options Infect Dis* 2003;5:69-80.

Klibanov OM, Raasch RH, Rublein JC. Changes in renal function after changes in antifungal drug therapy. *Am J Health-Syst Pharm* 2004;61:50-3.

Klibanov OM, Raasch RH, Rublein JC. Single versus combined antibiotic therapy for gram-negative infections. *Ann Pharmacother* 2004;38:332-7.

Raasch RH. Anidulafungin: a review of a new echinofungin antifungal agent. *Expert Rev Anti Infect Ther* 2004;2(4):499-508.

Abstracts

Jolly MK, Higgins S, Raasch RH. Heparin dosage requirements in deep venous thrombosis vs. pulmonary embolism. Abstract and poster presentation. Fifteenth Annual ASHP Midyear Clinical Meeting, San Francisco, December 10, 1980.

Raasch RH, Hak LJ, Benaim V, Heizer WD. Effect of intravenous fat emulsion on experimental pancreatitis. *J Parenter Enter Nutr.* 1981; 5:573 (abstract).

Hak LJ, Raasch RH, Hammer VB, Matthews TG, Heizer WD. Host tumor response to glucose and fat based TPN in rats. *J Parenter Enter Nutr.* 1982;6:576 (abstract).

Hak LJ, Kotter S, Raasch RH. Acceleration of peritoneal dialysis clearance with docusate sodium (DSS). *Drug Intell Clin Pharm.* 1983; 17:440-441.

Ulshen MH, Lyn-Cook L, Raasch RH. Effects of intraluminally administered EGF on small bowel mucosal proliferative response during fasting and refeeding. *Gastroenterology* 1986; 90(Pt2): 1673.

Ulshen MH, Raasch RH, Lyn-Cook LE. Effect of intraluminal epidermal growth factor (EGF) on mucosal recovery in the small bowel. *Gastroenterology* 1988; 94: A471.

Tartaglione T, Opheim K, vander Horst C, Raasch RH, Cheeseman S, High K. Pharmacokinetics of zidovudine in adult patients with HIV infection and hepatic disease. 6th AIDS Clinical Trials Group Meeting, Washington DC, July 11, 1989.

Barditch P, Polsky B, van der Horst C, Duncanson F, Kuye O, Ganes D, Faulkner R, Raasch R, Armstrong D, Petty B, Rae B, Yacobi A, Flexner C, Desjardins R. Hematologic toxicity of FLT appears to be AUC dependent. *Clin Pharmacol Ther* 1992;51:170.

Aweeka FT, Gambertoglio JG, van der Horst C, Polsky B, Korvick J, Raasch R, Jacobson MA. Pharmacokinetics (PK) of foscarnet (PFA) during alternating vs. concomitant ganciclovir (GCV) maintenance therapy for CMV retinitis. *Clin Pharmacol Ther* 1993;53:197.

Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W. Effects of ofloxacin on the pharmacokinetics of procainamide. *Clin Pharmacol Ther* 1994;55:166.

Moore K, Raasch R, Yuen G, Eron J, Martin D, Hussey E. Pharmacokinetics of lamivudine administered alone and with oral trimethoprim plus sulfamethoxazole in patients with human immunodeficiency virus infection. 96th Annual Meeting, American Society for Clinical Pharmacology and Therapeutics, San Diego, March 1995.

Kustra RP, Scott CS, Retsch-Bogart GZ, Raasch RH. The tobramycin postantibiotic effect on clinical *Pseudomonas aeruginosa* isolates from pediatric patients with cystic fibrosis. *Pharmacotherapy* 1996;16:501.

Wakeford JH, Raasch RH, Eron JJ, Groves J, Sadler B, Pagano G. Indinavir single dose pharmacokinetics after coadministration with GW141W94. American College of Clinical Pharmacy Annual Meeting, Phoenix, November 1997.

Evers LB, Raasch RH. Treatment gap in lipid lowering therapy. 32nd Annual Midyear Clinical Meeting, ASHP, Atlanta, December 1997.

Acosta EP, Gulick R, Katzenstein D, Haubrich R, Fischl M, Raasch R, Mills C, Pettinelli C, Remmel RP, Fletcher CV. Pharmacokinetic evaluation of saquinavir soft gel capsules/ritonavir or saquinavir/nelfinavir in combination with delavirdine and/or adefovir dipivoxil – ACTG 359. 6th Conference on Retroviruses and Opportunistic Infections, February 1999.

Brock TP, Ellis-Nielsen AD, Deloatch KH, Joyner PU, Raasch RH. Objective structured clinical exams (OSCE) as evaluative tools in pharmacy curricula. American Association of Colleges of Pharmacy Annual Meeting, July 1999.

Pittman AW, Shrewsbury RP, Bastow KF, Campbell WH, Christensen DB, Dell KA, Deloatch KH, Joyner PU, Raasch RH. CD-ROM/Web based ACPE self study. American Association of Colleges of Pharmacy Annual Meeting, 2000.
Williamson JC, Craft DW, Raasch RH, Butts JD. In vitro assessment of therapeutic options for urinary tract infections due to ampicillin-resistant enterococci. *Pharmacotherapy* 2000;20:349.

Theodore D, Raasch RH, Saal GB, Yeh YC. The short-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States, and

The long-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States. American Gastroenterological Association Annual Meeting, October 2000.

Deloatch KH, Joyner PU, Raasch RH. Integration of general and professional abilities across the Doctor of Pharmacy curriculum at the University of North Carolina. American Association of Colleges of Pharmacy Annual Meeting, 2001.

Strauss RP, van der Horst CM, Emrick CB, McKaig RG, Raasch RH, McQuiston CM. A campus-wide university course on AIDS: 15 years experience with interdisciplinary education as a public health intervention. XIV International AIDS Conference, July 2002.

Strauss RP, van der Horst CM, Emrick CB, McKaig RG, Raasch RH, McQuiston CM. Does teaching about HIV/AIDS impact on student attitudes and behaviors?: 15 years experience with interdisciplinary education as a public health intervention. American Public Health Association Annual Meeting, November 2002.

Davidson LA, Ousmanou AD, Raasch RH, Lindley C, Golding M. The effects of bupropion on autonomic response to mental stress, American College of Clinical Pharmacy Annual Meeting, November 2003.

Buie LW, Raasch RH. Risk of cross-reactivity of carbapenem antibiotics in penicillin-allergic patients, American Society of Health-System Pharmacists, December, 2004.

Dunn SP, Raasch RH. Empiric Use of Piperacillin/tazobactam Plus Ciprofloxacin and Subsequent Targeting of Therapy at a University Hospital, American Society of Health-System Pharmacists, December 2004.

Musick W, Barrow J, Williams D, Raasch RH. Use of antibiotic synergy studies in patients with cystic fibrosis, American Society of Health-System Pharmacists, December 2004.

Joyner JU, Raasch RH, Pittman AW. Building understanding through an interdisciplinary case conference, American Association of Colleges of Pharmacy, July 2005.